locally estimated scatterplot smoothing function proc loess Search Results


scatterplot smoothing loess  (Oxford Instruments)
99
Oxford Instruments scatterplot smoothing loess
Scatterplot Smoothing Loess, supplied by Oxford Instruments, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/scatterplot smoothing loess/product/Oxford Instruments
Average 99 stars, based on 1 article reviews
scatterplot smoothing loess - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier
igorpro8  (wavemetrics inc)
90
wavemetrics inc igorpro8
Igorpro8, supplied by wavemetrics inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/igorpro8/product/wavemetrics inc
Average 90 stars, based on 1 article reviews
igorpro8 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
locally estimated scatterplot smoothing function proc loess  (SAS institute)
90
SAS institute locally estimated scatterplot smoothing function proc loess
Locally Estimated Scatterplot Smoothing Function Proc Loess, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/locally estimated scatterplot smoothing function proc loess/product/SAS institute
Average 90 stars, based on 1 article reviews
locally estimated scatterplot smoothing function proc loess - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
locally estimated scatterplot smoothing regression  (RStudio)
90
RStudio locally estimated scatterplot smoothing regression
Pharmacokinetic curves of moxifloxacin with and without rifampicin coadministration of in‐house collected therapeutic drug monitoring (TDM) data for 400 mg of moxifloxacin only (A), 400 mg moxifloxacin with any dose of rifampicin (B), and 600 mg of moxifloxacin with any dose of rifampicin (C); median rifampicin dose for both group B and C was 1200 mg once daily (range, 450‐2000 mg). The x‐axis indicates time after last dose. Open circles and crosses indicate measured individual data from in‐house TDM data of patients with Mycobacterium tuberculosis or nontuberculous mycobacteria infections, respectively; the solid black lines indicate the fitted plasma concentration‐time curve using locally estimated <t>scatterplot</t> smoothing regression; and the gray area represents the 95% confidence interval around the regression. AUC 0‐24 , area under the plasma concentration–time curve from time 0 to 24 hours; C max , maximum plasma concentration.
Locally Estimated Scatterplot Smoothing Regression, supplied by RStudio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/locally estimated scatterplot smoothing regression/product/RStudio
Average 90 stars, based on 1 article reviews
locally estimated scatterplot smoothing regression - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
proc loess procedure  (SAS institute)
90
SAS institute proc loess procedure
Pharmacokinetic curves of moxifloxacin with and without rifampicin coadministration of in‐house collected therapeutic drug monitoring (TDM) data for 400 mg of moxifloxacin only (A), 400 mg moxifloxacin with any dose of rifampicin (B), and 600 mg of moxifloxacin with any dose of rifampicin (C); median rifampicin dose for both group B and C was 1200 mg once daily (range, 450‐2000 mg). The x‐axis indicates time after last dose. Open circles and crosses indicate measured individual data from in‐house TDM data of patients with Mycobacterium tuberculosis or nontuberculous mycobacteria infections, respectively; the solid black lines indicate the fitted plasma concentration‐time curve using locally estimated <t>scatterplot</t> smoothing regression; and the gray area represents the 95% confidence interval around the regression. AUC 0‐24 , area under the plasma concentration–time curve from time 0 to 24 hours; C max , maximum plasma concentration.
Proc Loess Procedure, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proc loess procedure/product/SAS institute
Average 90 stars, based on 1 article reviews
proc loess procedure - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Pharmacokinetic curves of moxifloxacin with and without rifampicin coadministration of in‐house collected therapeutic drug monitoring (TDM) data for 400 mg of moxifloxacin only (A), 400 mg moxifloxacin with any dose of rifampicin (B), and 600 mg of moxifloxacin with any dose of rifampicin (C); median rifampicin dose for both group B and C was 1200 mg once daily (range, 450‐2000 mg). The x‐axis indicates time after last dose. Open circles and crosses indicate measured individual data from in‐house TDM data of patients with Mycobacterium tuberculosis or nontuberculous mycobacteria infections, respectively; the solid black lines indicate the fitted plasma concentration‐time curve using locally estimated scatterplot smoothing regression; and the gray area represents the 95% confidence interval around the regression. AUC 0‐24 , area under the plasma concentration–time curve from time 0 to 24 hours; C max , maximum plasma concentration.

Journal: Journal of Clinical Pharmacology

Article Title: Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling

doi: 10.1002/jcph.1972

Figure Lengend Snippet: Pharmacokinetic curves of moxifloxacin with and without rifampicin coadministration of in‐house collected therapeutic drug monitoring (TDM) data for 400 mg of moxifloxacin only (A), 400 mg moxifloxacin with any dose of rifampicin (B), and 600 mg of moxifloxacin with any dose of rifampicin (C); median rifampicin dose for both group B and C was 1200 mg once daily (range, 450‐2000 mg). The x‐axis indicates time after last dose. Open circles and crosses indicate measured individual data from in‐house TDM data of patients with Mycobacterium tuberculosis or nontuberculous mycobacteria infections, respectively; the solid black lines indicate the fitted plasma concentration‐time curve using locally estimated scatterplot smoothing regression; and the gray area represents the 95% confidence interval around the regression. AUC 0‐24 , area under the plasma concentration–time curve from time 0 to 24 hours; C max , maximum plasma concentration.

Article Snippet: Individual plasma concentrations were plotted against time and a plasma concentration‐time curve was fitted using locally estimated scatterplot smoothing regression in R Studio version 1.1.463 (RStudio, Inc, Boston, Massachusetts) after which a C max was determined.

Techniques: Clinical Proteomics, Concentration Assay